Omalizumab Treatment in Patients with Severe Allergic Asthma

Tat T. S., ÇİLLİ A.

ISTANBUL MEDICAL JOURNAL, vol.18, no.3, pp.135-138, 2017 (ESCI) identifier

  • Publication Type: Article / Article
  • Volume: 18 Issue: 3
  • Publication Date: 2017
  • Doi Number: 10.5152/imj.2017.93653
  • Journal Name: ISTANBUL MEDICAL JOURNAL
  • Journal Indexes: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Page Numbers: pp.135-138
  • Keywords: Asthma, omalizumab, severe allergic asthma, uncontrolled allergic asthma, QUALITY-OF-LIFE, REAL-LIFE, ANTIBODY OMALIZUMAB, MODERATE, TOLERABILITY, MALIGNANCY, EFFICACY, THERAPY, SAFETY
  • Akdeniz University Affiliated: Yes

Abstract

Introduction: Omalizumab is a monoclonal antibody used for treating patients with severe allergic asthma. It has has been shown to be effective and is being increasingly used. This study aimed to evaluate the long-term efficacy and safety of omalizumab treatment in patients with severe allergic asthma.